Y mAbs Therapeutics (YMAB) — Financial Flexibility Index
Y mAbs Therapeutics (YMAB) has a Financial Flexibility Index of 0.06x as of June 2025. Free cash flow of $1.65 Million (operating CF $1.65 Million minus capex $0.00) represents 0% of total liabilities ($29.72 Million). Also explore net asset momentum of Y mAbs Therapeutics to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Y mAbs Therapeutics Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Y mAbs Therapeutics across 9 annual periods. Check Y mAbs Therapeutics (YMAB) strategic investment index to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Y mAbs Therapeutics (2016–2024)
Year-by-year free cash flow to debt coverage for Y mAbs Therapeutics. For the full company profile including market capitalisation, see Y mAbs Therapeutics (YMAB) total market value.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.56x | $-15.71 Million | $-15.71 Million | $27.90 Million | ▲ +44.4% |
| 2023 | -1.01x | $-27.23 Million | $-27.23 Million | $26.88 Million | ▲ +57.0% |
| 2022 | -2.36x | $-75.92 Million | $-75.92 Million | $32.23 Million | ▲ +24.2% |
| 2021 | -3.11x | $-101.59 Million | $-102.56 Million | $32.68 Million | ▲ +10.5% |
| 2020 | -3.47x | $-91.06 Million | $-91.23 Million | $26.21 Million | ▲ +15.2% |
| 2019 | -4.10x | $-71.53 Million | $-73.50 Million | $17.46 Million | ▼ -13.9% |
| 2018 | -3.60x | $-40.99 Million | $-41.23 Million | $11.40 Million | ▼ -129.5% |
| 2017 | -1.57x | $-15.64 Million | $-15.87 Million | $9.97 Million | ▲ +25.4% |
| 2016 | -2.10x | $-10.93 Million | $-11.17 Million | $5.20 Million | — |